The FREQ Procedure

## Example 3.7 Cochran-Mantel-Haenszel Statistics

The data set Migraine contains hypothetical data for a clinical trial of migraine treatment. Subjects of both genders receive either a new drug therapy or a placebo. Their response to treatment is coded as 'Better' or 'Same'. The data are recorded as cell counts, and the number of subjects for each treatment and response combination is recorded in the variable Count.

```data Migraine;
input Gender \$ Treatment \$ Response \$ Count @@;
datalines;
female Active  Better 16   female Active  Same 11
female Placebo Better  5   female Placebo Same 20
male   Active  Better 12   male   Active  Same 16
male   Placebo Better  7   male   Placebo Same 19
;
```

The following PROC FREQ statements create a multiway table stratified by Gender, where Treatment forms the rows and Response forms the columns. The CMH option produces the Cochran-Mantel-Haenszel statistics. For this stratified table, estimates of the common relative risk and the Breslow-Day test for homogeneity of the odds ratios are also displayed. The NOPRINT option suppresses the display of the contingency tables. These statements produce Output 3.7.1 through Output 3.7.3.

```proc freq data=Migraine;
tables Gender*Treatment*Response / cmh;
weight Count;
title 'Clinical Trial for Treatment of Migraine Headaches';
run;
```

Output 3.7.1 Cochran-Mantel-Haenszel Statistics
 Clinical Trial for Treatment of Migraine Headaches

The FREQ Procedure

Summary Statistics for Treatment by Response
Controlling for Gender

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)
Statistic Alternative Hypothesis DF Value Prob
1 Nonzero Correlation 1 8.3052 0.0040
2 Row Mean Scores Differ 1 8.3052 0.0040
3 General Association 1 8.3052 0.0040

For a stratified table, the three CMH statistics displayed in Output 3.7.1 test the same hypothesis. The significant -value (0.004) indicates that the association between treatment and response remains strong after adjusting for gender.

The CMH option also produces a table of relative risks, as shown in Output 3.7.2. Because this is a prospective study, the relative risk estimate assesses the effectiveness of the new drug; the "Cohort (Col1 Risk)" values are the appropriate estimates for the first column (the risk of improvement). The probability of migraine improvement with the new drug is just over two times the probability of improvement with the placebo.

The large -value for the Breslow-Day test (0.2218) in Output 3.7.3 indicates no significant gender difference in the odds ratios.

Output 3.7.2 CMH Option: Relative Risks
Estimates of the Common Relative Risk (Row1/Row2)
Type of Study Method Value 95% Confidence Limits
Case-Control Mantel-Haenszel 3.3132 1.4456 7.5934
(Odds Ratio) Logit 3.2941 1.4182 7.6515
Cohort Mantel-Haenszel 2.1636 1.2336 3.7948
(Col1 Risk) Logit 2.1059 1.1951 3.7108
Cohort Mantel-Haenszel 0.6420 0.4705 0.8761
(Col2 Risk) Logit 0.6613 0.4852 0.9013

Output 3.7.3 CMH Option: Breslow-Day Test
Breslow-Day Test for
Homogeneity of the Odds Ratios
Chi-Square 1.4929
DF 1
Pr > ChiSq 0.2218

 Previous Page | Next Page | Top of Page